| Primary |
| Asthma |
22.4% |
| Eczema |
16.4% |
| Chronic Obstructive Pulmonary Disease |
13.4% |
| Psoriasis |
9.0% |
| Product Used For Unknown Indication |
6.0% |
| Hypersensitivity |
4.5% |
| Pruritus |
4.5% |
| Erythrodermic Psoriasis |
3.0% |
| Ill-defined Disorder |
3.0% |
| Rash |
3.0% |
| Ear Pruritus |
1.5% |
| Alopecia |
1.5% |
| Atopy |
1.5% |
| Dermatitis |
1.5% |
| Dermatitis Contact |
1.5% |
| Dermatosis |
1.5% |
| Inhalation Therapy |
1.5% |
| Multiple Allergies |
1.5% |
| Nasal Congestion |
1.5% |
| Nasal Polyps |
1.5% |
|
| Haemoptysis |
14.7% |
| Drug Ineffective |
8.8% |
| Cataract |
5.9% |
| Dermatitis Contact |
5.9% |
| Overdose |
5.9% |
| Palpitations |
5.9% |
| Product Substitution Issue |
5.9% |
| Sudden Death |
5.9% |
| Urinary Tract Infection |
5.9% |
| Urticaria |
5.9% |
| Anaphylactic Reaction |
2.9% |
| Angioedema |
2.9% |
| Anosmia |
2.9% |
| Application Site Reaction |
2.9% |
| Arthralgia |
2.9% |
| Blood Pressure Increased |
2.9% |
| Bronchospasm |
2.9% |
| Bronchospasm Paradoxical |
2.9% |
| Candidiasis |
2.9% |
| Cushing's Syndrome |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
47.3% |
| Drug Use For Unknown Indication |
13.6% |
| Hypertension |
6.3% |
| Asthma |
4.6% |
| Sinus Disorder |
4.4% |
| Eczema |
3.4% |
| Chronic Obstructive Pulmonary Disease |
3.1% |
| Accidental Exposure |
2.1% |
| Dermatitis Atopic |
1.9% |
| Muscle Spasms |
1.9% |
| Pain |
1.7% |
| Hypersensitivity |
1.6% |
| Fatigue |
1.2% |
| Pruritus |
1.2% |
| Coronary Artery Disease |
1.1% |
| Rash |
1.1% |
| Blister |
1.0% |
| Eczema Infantile |
1.0% |
| Convulsion |
0.9% |
| Drug Exposure During Pregnancy |
0.9% |
|
| Nausea |
15.6% |
| Vestibular Disorder |
14.3% |
| Sudden Death |
13.0% |
| Drug Ineffective |
7.8% |
| Pco2 Decreased |
6.5% |
| Chronic Obstructive Pulmonary Disease |
3.9% |
| Red Blood Cell Count Decreased |
3.9% |
| Vision Blurred |
3.9% |
| Aspiration |
2.6% |
| Blister |
2.6% |
| Candidiasis |
2.6% |
| Condition Aggravated |
2.6% |
| Cushing's Syndrome |
2.6% |
| Drug Effect Decreased |
2.6% |
| Drug Resistance |
2.6% |
| Hypoventilation |
2.6% |
| Myocardial Infarction |
2.6% |
| Neuroleptic Malignant Syndrome |
2.6% |
| Oral Intake Reduced |
2.6% |
| Oropharyngeal Discomfort |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.8% |
| Drug Use For Unknown Indication |
26.8% |
| Asthma |
5.9% |
| Pain |
4.2% |
| Rheumatoid Arthritis |
4.1% |
| Hypertension |
3.9% |
| Hypersensitivity |
3.9% |
| Psoriasis |
2.6% |
| Prophylaxis |
2.5% |
| Diabetes Mellitus |
2.1% |
| Hiv Infection |
2.0% |
| Depression |
1.8% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Multiple Myeloma |
1.6% |
| Smoking Cessation Therapy |
1.6% |
| Constipation |
1.6% |
| Graft Versus Host Disease |
1.2% |
| Insomnia |
1.2% |
| Osteoporosis |
1.0% |
|
| Vomiting |
13.1% |
| Weight Decreased |
8.5% |
| Nausea |
7.4% |
| Drug Ineffective |
6.0% |
| Rash |
5.7% |
| Tachycardia |
5.3% |
| Tremor |
5.3% |
| Vision Blurred |
5.3% |
| Pain In Extremity |
4.6% |
| Urinary Retention |
4.6% |
| Unresponsive To Stimuli |
3.9% |
| Death |
3.5% |
| Electrocardiogram Qt Prolonged |
3.5% |
| Pain |
3.5% |
| Weight Increased |
3.5% |
| Asthma |
3.2% |
| Deep Vein Thrombosis |
3.2% |
| Pruritus |
3.2% |
| Thrombocytopenia |
3.2% |
| Viral Pharyngitis |
3.2% |
|
| Interacting |
| Hiv Infection Cdc Category A1 |
50.0% |
| Asthma |
33.3% |
| Rhinitis Allergic |
16.7% |
|
|
